

1 **Multiple effects of TNF α inhibitors on the development of the adaptive immune response**
2 **after SARS-CoV-2 vaccination**

3
4 Ulf Martin Geisen^{1*}, Ruben Rose^{2*}, Franziska Neumann³, Maria Ciripoi¹, Lena Vullriede¹,
5 Hayley M Reid¹, Dennis Kristopher Berner¹, Federico Bertoglio⁴, Paula Hoff⁵, Michael Hust⁴,
6 Ann Carolin Longardt, Thomas Lorentz³, Gabriela Rios Martini^{7,9}, Carina Saggau⁷, Jan Henrik
7 Schirmer¹, Maren Schubert⁴, Melike Sümbül⁹, Florian Tran^{8,10}, Mathias Voß², Rainald
8 Zeuner¹, Peter J Morrison⁹, Petra Bacher^{7,8}, Helmut Fickenscher², Sascha Gerdes⁹, Matthias
9 Peipp¹¹, Stefan Schreiber^{8,10}, Andi Krumbholz^{2,3‡}, Bimba Franziska Hoyer^{1‡}

10
11 1 Medical Department I, Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein
12 Campus Kiel, Kiel, Germany

13 2 Institute for Infection Medicine, Christian-Albrecht University of Kiel and University Medical Center
14 Schleswig-Holstein, Campus Kiel, Kiel, Germany

15 3 Labor Dr. Krause und Kollegen MVZ GmbH, Kiel, Germany

16 4 Institute of Biochemistry, Biotechnology, and Bioinformatics, Department of Biotechnology, Technische
17 Universität Braunschweig, Braunschweig, Germany.

18 5 Department of Rheumatology, Endokrinologikum-Gruppe, Berlin, Germany

19 6 Department of Pediatrics, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany

20 7 Institute of Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany

21 8 Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel, Germany

22 9 Department for Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany

23 10 Department for Internal Medicine I, University Medical Center Schleswig-Holstein Campus Kiel

24 11 Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Medical Center
25 Schleswig-Holstein Campus Kiel, Kiel, Germany

26
27 * ‡These authors contributed equally

28
29 **Abstract**

30 *Objectives:*

31 The humoral immune response to SARS-CoV-2 vaccination in patients with chronic
32 inflammatory disease (CID) declines more rapidly with TNF α inhibition. Furthermore, the
33 efficacy of current vaccines against Omicron variants of concern (VOC) including BA.2 is
34 limited. Alterations within immune cell populations, changes in IgG affinity and the ability to
35 neutralise a pre-VOC strain and the BA.2 virus were investigated in these at-risk patients.

36 *Methods:*

37 Serum levels of anti-SARS-CoV-2 IgG, IgG avidity and neutralising antibodies (NA) were
38 determined in anti-TNF α patients (n=10) and controls (n=24 healthy individuals; n=12
39 patients under other disease-modifying anti-rheumatic drugs, oDMARD) before and after the
40 second and third vaccination by ELISA, immunoblot and live virus neutralisation assay. SARS-
41 CoV-2-specific B- and T cell subsets were analysed by multicolour flow cytometry.

42 *Results:*

43 IgG avidity and anti-pre-VOC NA titres decreased faster in anti-TNF α recipients than in
44 controls 6 months after the second vaccination (healthy individuals: avidity: p \leq 0.0001; NA:
45 p=0.0347; oDMARDs: avidity: p=0.0012; NA: p=0.0293). Total plasma cell counts were
46 increased in anti-TNF α patients (Healthy individuals: p=0.0344; oDMARDs: p=0.0254),
47 whereas absolute numbers of SARS-CoV-2-specific cells were comparable 7 days after
48 vaccination. These patients had lower BA.2 NA titres compared to both other groups, even
49 after the third vaccination.

50 *Conclusions:*

51 We show a reduced SARS-CoV-2 neutralising capacity in patients under TNF α blockade. In
52 this cohort, the plasma cell response appears to be less specific and show stronger
53 bystander activation. While these effects were observable after the first two vaccinations
54 and with older VOC, the differences in responses to BA.2 were magnified.

55

56 **What is already known on this topic** – Patients with chronic inflammatory diseases treated
57 with TNF α inhibitors show a greater decrease in SARS-CoV-2 IgG 6 months after the second
58 vaccination than patients taking oDMARDs and healthy individuals.

59

60 **What this study adds** – Antibodies from patients taking TNF α blockers have a lower SARS-
61 CoV-2 neutralising capacity and maturity. Plasma cells from these patients exhibit less
62 specific immune reaction. SARS-CoV-2-specific T cells are less activated. Neutralisation
63 against BA.2 is drastically reduced even after the third vaccination.

64

65 **How this study might affect research, practice or policy** – This study emphasizes the need
66 to protect vulnerable groups such as patients using TNF inhibitors. They could benefit from
67 Omicron-adapted vaccination, but most likely they need to be protected by additional
68 means other than vaccination.

69

70 **Keywords:** COVID19, Tumor Necrosis Factor Inhibitors, Vaccination, Autoimmune Diseases

71

72 **Word Count: 3091 (max 3500)**

73 **Abstract: 250**

74

75 **Introduction**

76 The current SARS-CoV-2 pandemic poses a particular challenge for patients with chronic
77 inflammatory disease (CID) receiving immunosuppressive therapies. For example, certain
78 immunosuppressive therapies/pharmaceuticals (e.g., B cell depleting therapies,
79 antimetabolites such as methotrexate, high-dose corticosteroids) are known to interfere
80 with SARS-CoV-2 vaccine efficacy.(1) However, long-term data from this population on
81 immune response to the vaccines are lacking.

82

83 Previously, we found that CID patients under tumour necrosis factor alpha (TNF α) inhibiting
84 therapy initially showed a largely normal, albeit slightly delayed, immune response to SARS-
85 CoV-2 mRNA vaccines which was followed by a rapid decline of anti-spike (S) and virus-
86 neutralising antibody (NA) levels compared to patients receiving other disease modifying
87 anti-rheumatic drugs (oDMARDs) and healthy controls.(2) While the difference in anti-S
88 antibody levels was marginal at day 7 and absent at day 14 after the second vaccination,
89 these patients had significantly lower anti-S IgG levels six months after vaccination.
90 Moreover, the neutralising capacity of serum in CID patients treated with TNF α inhibitors
91 was dramatically reduced at the sixth month after vaccination, as shown by a surrogate
92 neutralisation assay.(3) This impairment of adaptive immunity during anti-TNF α treatment
93 has also been confirmed by other research groups, including live virus neutralisation data
94 using the Delta variant of concern (VOC) as antigen.(4, 5) Compared with healthy controls,
95 anti-S IgA levels were decreased in CID patients at all time points after vaccination,
96 suggesting impaired mucosal immunity.(3) It remains unclear what biological mechanisms
97 lead to this impaired antibody response and whether these differences indicate generally
98 lower immunity after vaccination compared with controls. The relationship between B cells

99 and T cells during SARS-CoV-2 vaccination is not fully understood, as humoral and T cell
100 immunity appear to depend on B cell counts before vaccination.(6) In addition, data from
101 immunocompromised kidney transplant patients show that T cell activity after vaccination
102 correlates with the magnitude of the antibody response,(7) while high T cell activity has
103 been observed in B cell depleted patients after immunisation.(8)

104
105 Sera from vaccinated healthy individuals show only limited neutralisation capacity against
106 Omicron (B.1.1.529) VOC.(9, 10) This variant, consisting of several sublineages, including
107 BA.1 and BA.2, is considered a separate serotype that is antigenically distinct from the
108 original Wuhan strain (designated here as wild-type, wt, or pre-VOC) and other VOCs.(11)
109 The marked immune escape of BA.1 and BA.2 and the importance of booster vaccination for
110 the development of NA against both sublineages have recently been demonstrated,(10)
111 especially the need of mRNA boost immunisations for persons vaccinated with inactivated
112 viruses.(12)

113
114 Only limited data are available on the persistence of NA against various SARS-CoV-2 lineages
115 (including Omicron) in CID patients receiving anti-TNF α therapy after double vaccination.
116 Virtually no data are available on the development of binding strength (avidity) of vaccine-
117 induced IgG antibodies, which is considered an expression of their maturity and optimal
118 epitope binding (13) (14), for this group of patients, nor are there any data on the
119 development of cellular immunity.

120
121 The aim of this study is to clarify the influence of immunosuppressive therapy on the
122 development of adaptive immunity after SARS-CoV-2 vaccination. To this end, the quality
123 and quantity of SARS-CoV-2-specific B cells, plasmablasts, T cells, and antibodies were
124 measured at different time points after the second vaccination. We report differential
125 development of anti-BA.2 NAs after a third dose of vaccine.
126

127 **Methods**

128 *Patient recruitment and biosampling*

129 The study was approved by the ethics committee of the Christian-Albrecht University Kiel
130 (D409/21). There was no patient and public involvement in conducting the study.
131 Recruitment of patients and repetitive biosampling was performed as previously
132 described.(2) The SAVE-CID cohort consists of 47 healthcare workers and other risk groups
133 who received their first SARS-CoV-2 vaccination in January 2021 followed by a second
134 vaccination 5 or 3 weeks later. Samples taken 7 days after the third vaccination were also
135 examined in 12 patients. All patients received BNT162b2 (Comirnaty, Pfizer/BioNTech) or
136 mRNA-1273 (Spikevax, Moderna). Biosampling and data acquisition as well as data on
137 antibody concentration, surrogate neutralisation data and clinical characterisation of this
138 cohort has already been published.(2, 3) The patient groups were age and gender matched
139 resulting in mean ages of 43 (TNF α inhibitor, median: 42.5), 41.25 (Healthy Control, median:
140 39) and 41.63 (oDMARDs, median: 46).

141

142 *Production of SARS-CoV-2 S1 proteins*

143 S1 domain of the S protein(GenBank: MN908947) with different tags were baculovirus-free
144 produced in High Five cells (Thermo Fisher Scientific) by transient transfection as previously
145 described.(15, 16) Protein purification was performed depending 1 or 5 mL column on Äkta
146 go (Cytiva), Äkta Pure (Cytiva), or Profina System (BIO-RAD). HiTrap Fibro Prisma (Cytiva)
147 was used as resins for Protein A purification (Fc-tagged proteins). For His-tag purification of
148 insect cell supernatant HisTrapexcel column (Cytiva) was used. All purifications were
149 performed according to the manufacturer's manual. S1-HIS was further purified by SEC by a
150 16/600 Superdex 200 kDa pg (Cytiva).

151

152 *Isolation of peripheral blood mononuclear cells (PBMC) and Flow Cytometry*

153 PBMCs from EDTA blood were isolated within three hours of blood collection by density
154 gradient centrifugation (Biocoll, Bio&SELL GmbH, Feucht, Germany). Afterwards, 4×10^6
155 PBMCs were incubated with his-tagged S1 protein (own protein or Euroimmun, Lübeck,
156 Germany).(9) PBMCs were then stained with pre-mixed antibodies (CD19-PerCP-Vio-700
157 (REA657, Miltenyi Biotec, Bergisch-Gladbach, Germany), CD20-PE-Cio770 (REA780, Miltenyi
158 Biotec), CD3-Pacific Blue (OKT3, Biolegend, San Diego, USA), CD14 Pacific Blue (M5E2,
159 Biolegend), CD27-APC (M-T271, Biolegend), anti-HIS-PE (JO95-G46, Biolegend), Biolegend),
160 HLA-DR-VioGreen (REA805, Miltenyi Biotec), CD138-BV605 MI15, Biolegend)) and analysed
161 using a MacsQuant 16 Cytometer (Miltenyi Biotec, Bergisch-Gladbach, Germany). Secondary
162 staining using AF-700 coupled S1-fc protein were used as gating and staining control to
163 exclude false positive events (see figure S1 and S2 for more information). For the calculation
164 of immune cells per blood volume, 50 μ L of whole blood was stained, (CD3-Pacific Blue
165 (Biolegend), CD14-FITC (REA599, Miltenyi Biotec), CD4-PE (Vit4, Miltenyi Biotec), CD19-
166 PerCP-Vio700 and CD45-APC-Vio770 (H130, Biolegend)), lysed, (Red blood lysis, BD) and
167 measured on a MACSQuant 16 (Miltenyi Biotec). The cell counts per 50 μ L blood for each
168 sample were used to calculate all other cell counts from the PBMC staining. Staining and
169 measurement were performed in PBS containing 1% BSA, 0.5% EDTA and 0.1% sodium azide.

170

171 *Measurement of Antibody Secreting Cells by Three-Colour Fluorospot*

172 PBMCs were isolated as described above and different T cell numbers were incubated for
173 three hours in a 96-well 0.45 μ M PVDF Immobilon-FL membrane plate (Merck Millipore,
174 Burlington, MS, USA) which was pre-coated with SARS-CoV-2 protein or FAB2-fragments

175 against Immunoglobulins A, M (both Southern Biotech, Birmingham, USA), G (Jackson
176 Immunoresearch, Cambridge, UK) and blocked with 15% FCS in PBS. After 3 washing steps
177 with deionised water, the wells were stained using IgA-FITC, IgG-FC-AF555 and IgM-AF647
178 (all Southern Biotech). Measurement was performed on a Bioreader 6000Fb equipped with
179 Eazyreader software (Bio-SYS, Karben, Germany)

180

181 *Antigen-reactive T cell enrichment (ARTE)*

182 The ARTE was performed as previously described (17-20). In brief, $0.5-1 \times 10^7$ PBMCs were
183 stimulated for 7 hours with $0.5 \mu\text{g/peptide/ml}$ SARS-CoV-2 S peptide pool (JPT, Berlin,
184 Germany) in presence of $1 \mu\text{g/ml}$ CD40 and $1 \mu\text{g/ml}$ CD28 pure antibody (both Miltenyi
185 Biotec, Bergisch Gladbach, Germany). $1 \mu\text{g/ml}$ Brefeldin A (Sigma Aldrich) was added for the
186 last two hours. Cells were magnetically isolated using the CD154 MicroBead Kit (Miltenyi
187 Biotec). After surface staining with CD4-APC-Vio770 (M-T466), CD8-VioGreen (REA734),
188 CD14-VioGreen (REA599), CD20-VioGreen (LT20) (all Miltenyi Biotec), CD45RA-PE-Cy5
189 (HI100), PD-1 Brilliant Violet 605 (EH12.2H7), CCR7-Brilliant-Violet-785 (G043H7) (all
190 BioLegend), cells were fixed, permeabilized and stained intracellular with CD154-FITC
191 (REA238), IL-21-PE (REA1039) (both Miltenyi Biotec), IFN- γ -PerCP-Cy5.5 (4S.B3), TNF α -
192 Brilliant-Violet-650 (MAb11), IL-10-PE-Dazzle (JES3-9D7) (all BioLegend), IL-2-BV711
193 (5344.111), Ki-67-Alexa Fluor 700 (B56) (both BD Biosciences). Viability 405/520 Fixable Dye
194 (Miltenyi Biotec) was used to exclude dead cells. Data were acquired on a LSR Fortessa (BD
195 Bioscience, San Jose, CA, USA). CD154⁺ background cells enriched from the non-stimulated
196 control were subtracted and frequencies of antigen-specific T cells were determined based
197 on CD154⁺ T cells after enrichment, normalised to the total number of CD4⁺ T cells applied
198 on the column.

199

200 *Binding strength (avidity) of SARS-CoV-2 IgG antibodies*

201 The IgG avidity was assessed with the *recomLine* SARS-CoV-2 IgG assay on a Dynablot Plus
202 system together with a BLOTrix reader and the recomScan software (all from Mikrogen
203 GmbH, Neuried, Germany) as reported previously.(21) This immunoblot consists of a
204 nitrocellulose strip separately carrying recombinant nucleocapsid protein (NP) and the S1-
205 and RBD-subunits of the S protein. Binding of IgG to these SARS-CoV-2 antigens in presence
206 or absence of avidity reagent was automatically measured and assigned to four categories:
207 no avidity detectable (=0), low avidity (=1), intermediate avidity (=2) and high (=3)
208 avidity.(22)

209

210 *Measurement of neutralising antibodies against a pre-VOC strain and a BA.2 strain*

211 Sera were tested in triplicate using a Vero cell-based live virus neutralisation test (cVNT) in
212 96-well format under biosafety level 3 conditions, as previously reported.(10, 22) In brief,
213 sera were diluted 1:10 to 1:1280 in cell culture medium free of fetal calf serum. As antigens
214 for the cVNT, we used either 50 plaque-forming units per well of a B.1 strain (pre-VOC of
215 2020) or an Omicron BA.2 strain, which we had previously isolated (23) and characterised by
216 whole-genome sequencing.(10, 23) After four (pre-VOC) or six (BA.2) days of incubation,
217 cells were fixed by addition of paraformaldehyde and stained with an aqueous crystal violet
218 methanol solution. Serum dilutions (titres) > 1:10 that prevented the formation of a
219 cytopathic effect in ≥ 2 wells were considered to contain neutralising antibodies (NA); if no

220 exact titre could be given, the geometric mean of the two adjacent titres was calculated.(10,
221 22)

222

223 *Data analysis and statistics*

224 Flow cytometry data was analysed using FlowJo v10 (BD Bioscience). Statistical analyses and
225 graphs were prepared using RStudio (version 2022.02.0+443) and Prism 8 (GraphPad
226 Software, LLC). For analysis of differences between the groups, Kruskal-Wallis Test and non-
227 parametric pairwise comparisons were performed.

228

229 **Results**

230

231 **Anti-S-IgG-antibody concentrations, IgG avidity and neutralisation efficacy decrease 6** 232 **months after vaccination**

233 Under TNF α inhibitor therapy, anti-S-IgG levels after the second immunisation were
234 significantly lower than in patients receiving oDMARDs or in healthy controls (figure 1a).
235 None of the subjects showed anti-NP IgG reactivity, making infection breakthrough unlikely
236 (data not shown). The IgG avidity and neutralisation capacity against the pre-VOC strain
237 were high in all tested groups 14 days after second vaccination (avidity: median avidity index
238 (MAI) = 3; NA: geometric mean titres (GMT)=1:98–1:234)(figure 1B, C). Six months after
239 second vaccination, IgG avidity and pre-VOC NA titres significantly decreased in TNF α -
240 inhibitor treated vaccinees (n=8; avidity: MAI=1.25; NA: GMT=1:2) compared to patients
241 receiving oDMARDs (n=7; avidity: MAI=3, p=0.0012; NA: GMT=1:38, p=0.0293) and healthy
242 controls (n=12; avidity: MAI=3, p \leq 0.0001; NA: GMT=1:25, p=0.0347) (figure 1A). Relative to
243 the pre-VOC strain, anti-BA.2 NA titres were significantly lower than against the pre-VOC
244 strain in all three groups at day 14 after the second vaccination (GMT=1:2-1:4 vs. GMT=1:98-
245 1:234; p=0.0001-0.0072) and were not detected after six months (GMT<1:10, figure 1D). At 7
246 days after the third vaccination, anti-BA.2 NAs were detectable in all subjects except
247 patients taking a TNF α blocker (n=4 per group; GMT=1:62-1:95 vs. GMT=1:3). At this time
248 point, IgG avidity was high in all subjects except one patient receiving anti-TNF α treatment.

249

250 **Plasma cell populations are altered in patients using TNF α blockers**

251 Patients under TNF α inhibiting therapy showed higher numbers of plasmablasts in the
252 peripheral blood 7 days after the second vaccination (median: 9.153cells/ μ L) compared to
253 patients receiving oDMARDs (median: 2.205cells/ μ L, p=0.0254) (figure 2A) and healthy
254 controls (2.657 cells/ μ L, p=0.0344).

255 When comparing SARS-CoV-2 specific plasma cells at the same timepoint, no differences
256 between patients on TNF α blockade (median 0.295 cells/ μ L) and healthy controls (median
257 0.333 cells/ μ L) were detected, while patients treated with oDMARDs other than TNF α
258 inhibitors had significantly lower cell numbers compared to healthy controls (median: 0.204
259 cells/ μ L; p=0.0015) (figure 2B).

260 Anti-TNF α treated patients generally displayed more peripheral blood IgA plasma cells than
261 controls and patients receiving oDMARDs (figure 2C). This trend became significant on day
262 14 after vaccination for patients under oDMARDs (median 0.404 cells/ μ L) and TNF α blockers
263 (median 1.818 cells/ μ L; p=0.0397).

264 With regards to SARS-CoV-2-specific IgA-plasma cells, counts were lower in the anti-TNF α
265 group on day 7 after the second vaccination (median: 0.016 cells/ μ L) compared to healthy
266 controls (median: 0.052 cells/ μ L; p=0.0203) and patients treated with oDMARDs
267 (median:0.035 cells/ μ L; p=0.0299) (figure 1D).

268 Overall numbers of mature circulating CD138⁺ plasma cells were higher in patients on TNF α
269 blockade (median: 0.101 cells/ μ L) than in healthy controls (median: 0.031 cells/ μ L;
270 $p=0.0055$) and patients treated with oDMARDs (median: 0.019 cells/ μ L; $p=0.0015$) on day 14
271 after second vaccination (figure 2E). Differences at time points between the first and the
272 second vaccination were not significant. We were not able to detect differences in the
273 number of SARS-CoV-2 specific plasma cells. However, on day 7 after second vaccination,
274 healthy controls had higher numbers of circulating CD138⁺ plasma cells in the peripheral
275 blood (median: 0.004 cells/ μ L) than patients using TNF α inhibitors (median: 0.002 cells/ μ L;
276 $p=0.0055$) or receiving oDMARDs (median: 0.001 cells/ μ L; $p=0.0026$) (figure 2F).

277

278 **Anti-TNF α treatment does not change the number of SARS-CoV-2 specific antibody** 279 **secreting cells**

280 Relative to the other two sample groups, anti-TNF α patients showed a pronounced increase
281 in SARS-CoV-2 specific antibody secreting cells (ASCs) of the IgM isotype at day 7 post
282 second vaccination, while total numbers of ASC of all other isotypes remained comparable
283 between groups (figure 3A). Analysing spot size in our Fluorospot assays as a surrogate for
284 the amount of secreted antibody per cell, both patient groups generally displayed larger
285 spot sizes suggesting increased antibody secretion per ASC (figure 3B). These differences
286 were not significant except for IgA ($p=0.0026$ for TNF vs. Healthy Control and $p=0.001$ for
287 oDMARDs vs. Healthy Control). No differences were detected between the two patient
288 groups. The number of ASCs correlated well with SARS-CoV-2 serum IgG levels and the
289 number of SARS-CoV-2 positive plasmablasts at the same timepoint (figure 3C-D). No
290 antigen specific plasma cells were detected in the blood of any participant before the first
291 vaccination (data not shown).

292

293 **SARS-CoV-2 specific T cells show signs of delayed activation**

294 SARS-CoV-2 S-specific CD4⁺ T cells could be detected at similar frequencies in all groups
295 after second vaccination (figure 4A). We also observed no differences in cytokine production
296 (TNF α , IFN γ , IL-2, IL-21 or IL-10) by the S-specific T cells between TNF α patients, oDMARDs
297 and controls (figure 4B). In contrast, TNF α patients showed significantly lower expression of
298 PD-1 and a trend towards increased levels of Ki-67, suggesting a delayed or still ongoing
299 activation of these cells (figure 4C).

300

301 **Discussion**

302 To our knowledge, we present the first such comprehensive data on the longitudinal course
303 of adaptive immunity in CID patients vaccinated against SARS-CoV-2 undergoing TNF α
304 blockade.

305 These patients show an altered immune response after vaccination relative to oDMARD
306 patients and healthy controls in the absence of breakthrough infections, suggesting that
307 such individuals should be monitored more closely for loss of SARS-CoV-2 immunity.

308 Most strikingly, anti-TNF α patients exhibited a stronger decrease in IgG avidity and
309 neutralisation capacity 6 months after vaccination and did not acquire NAs against BA.2 after
310 a third vaccination. To our knowledge this is the first report concerning the long-term
311 neutralisation efficacy against BA.2 VOC within this patient population after vaccination.
312 While the neutralisation efficiency against the initial pre-VOC wt strain was marginally lower
313 in anti-TNF α -treated patients 14 days after second vaccination compared to the other
314 groups, this difference was more pronounced against the BA.2 strain where overall low
315 neutralisation was detected. Six months after second vaccination, BA.2 NAs were not

316 detected in any of the three study groups, suggesting that the S antigen of this VOC is
317 relevantly different from that of wt and derived VOCs, consistent with recent studies.(10, 24)
318 The loss of IgG avidity was unexpected as anti-TNF α patients displayed similarly high IgG
319 avidity as the other groups at day 14 post second vaccination. Conversely, other studies have
320 shown, that the avidity of anti- SARS-CoV-2 IgG increases during the subsequent months
321 after vaccination.(13) This decline of avidity several months after the vaccination anti-TNF α
322 patients has not been previously reported.

323 In addition, various changes in the plasmablast compartment of patients were observed in
324 response to vaccination. Hence, patients using TNF inhibitors had higher numbers of plasma
325 cells after the first vaccination (d0.2) relative to the two other groups. These differences
326 increase after the second vaccination, suggesting a stronger immune reaction. The
327 frequency of SARS-CoV-2 specific plasma cells within this population was decreased in the
328 patient groups compared to controls. The absolute number of SARS-CoV-2 specific
329 plasmablasts however was comparable to the other groups, suggesting that the immune
330 reaction triggered under TNF α therapy is more unspecific.

331
332 Higher numbers of mature CD138⁺ plasmablasts were detected within the non-SARS-CoV2-
333 specific plasma cells from anti-TNF α patients. These cells are usually found in the bone
334 marrow.(25) The difference in maturity between S-specific and non-specific plasma cells may
335 represent a reduced capacity to form long-lived specific plasma cells in anti-TNF α patients.
336 However, assessment of these cells in the peripheral blood might not reflect their state in
337 the bone marrow and our measurements after second vaccination may be too early for the
338 detection of long-lived SARS-CoV-2-specific plasma cells. We also noted that a large
339 proportion of these CD138⁺ plasma cells expressed HLA-DR (Figure S4). These phenotypically
340 mature (CD138⁺) and antigen presenting plasmablasts (HLA-DR) were also described in
341 patients with severe COVID19 (26) their function remains unclear.

342
343 Interestingly, although broadly homogeneous, there were two outliers in our cohort of anti-
344 TNF α patients. One patient had consistently high antibody concentrations, high IgG avidity
345 and NAs at 6 months. The other patient had consistently low values for all three parameters.
346 These outliers show the importance of individual monitoring of patients at risk of reduced
347 immunity after vaccination.

348
349 Our data demonstrate that TNF α inhibitors affect the adaptive immune response after SARS-
350 CoV-2 vaccination. This is reflected in the development of IgG avidity, virus neutralising
351 capacity, plasma cell and T cell populations. We recommend regular measurement of anti-
352 SARS-CoV-2 IgG levels and especially NA titres in these patients, as this group may benefit
353 from early booster vaccination. To our knowledge, current commercial anti-SARS-CoV-2
354 antibody tests are based on antigens still derived from the wild type. However, if available,
355 assays adapted to the currently circulating variants should preferably be used. In addition,
356 the development of variant-specific surrogate neutralisation tests would be desirable, as
357 these, unlike live virus neutralisation assays, can also be used in routine laboratories. CID
358 patients on TNF α inhibitor therapy who have no, or low detectable antibody levels should be
359 particularly protected from COVID-19. Following SARS-CoV-2 infection, these patients might
360 require close monitoring and early administration of monoclonal antibodies that also cover
361 currently circulating VOC. In addition, we recommend the use of a vaccine adapted to the
362 current VOC as soon as it becomes available.

363

364 The mechanisms leading to decreased antibody response during immunosuppressive
365 treatment need to be further explored to improve vaccine regimens for these high-risk
366 patients.

367

368

369

370 Contributors

371 Study design: UMG, FT, MP, SS, AK, HF, BFH. Sample collection: DKB,ACL, JHS, MS, FT, RZ, SG.

372 Experiments and data analysis: UMG, RR, FN, MC, LV, HMR, PB, FB, MH, MV, AK, HF and BFH.

373 Tables and figures: UMG, RR and BFH. Data interpretation: UMG, RR, PB, AK, HF and BFH.

374 Writing of the manuscript: UMG, PH, PJM, AK and BFH. Critical proof reading of the
375 manuscript: all authors.

376

377 Acknowledgement

378

379 We thank Meike Zahnen (UKSH, Rheumatology), Ina Martens (UKSH, Rheumatology), Sina
380 Müller (Labor Dr. Krause und Kollegen) and Carina Bäumlner (Labor Dr. Krause und Kollegen)
381 for excellent technical and organisational assistance.

382 We acknowledge the support of the European Union for the ATAC (“antibody therapy
383 against corona”. Horizon2020 number 101003650) consortium.

384 The authors thank Mikrogen GmbH, Neuried, Germany, for providing free or discounted kits
385 for IgG avidity detection.

386

387 Funding

388 Cross-funded by Bundesministerium für Bildung und Forschung (Grant GAIN_01GM1910D),
389 DIO002/CoVispect research grant from the Land Schleswig-Holstein, the German Network
390 University Medicine NUM NaFoUniMedCovid19“ (FKZ: 01KX2021), project COVIM and by
391 the Deutsche Forschungs-Gemeinschaft Cluster of Excellence Precision Medicine in Chronic
392 Inflammation and Transregio 130. BFH, PH and SS received funding from Pfizer and other
393 companies.

394

395 Competing Interests

396 None declared

397

398

399

References

400

401 1. Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al.
402 Antibody development after COVID-19 vaccination in patients with autoimmune diseases in
403 the Netherlands: a substudy of data from two prospective cohort studies. *Lancet Rheumatol.*
404 2021;3(11):e778-e88.

405 2. Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al.
406 Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic
407 inflammatory conditions and immunosuppressive therapy in a monocentric cohort. *Annals*
408 *of the rheumatic diseases.* 2021:annrheumdis-2021-220272.

409 3. Geisen UM, Sümbül M, Tran F, Berner DK, Reid HM, Vullriede L, et al. Humoral
410 protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. *RMD*
411 *open.* 2021;7(3).

- 412 4. Chen RE, Gorman MJ, Zhu DY, Carreño JM, Yuan D, VanBlargan LA, et al. Reduced
413 antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated
414 individuals receiving tumor necrosis factor- α inhibitors. *Med (N Y)*. 2021;2(12):1327-41.e4.
- 415 5. Farroni C, Picchianti-Diamanti A, Aiello A, Nicastrì E, Laganà B, Agrati C, et al. Kinetics
416 of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination
417 in Patients With Rheumatoid Arthritis. *Frontiers in immunology*. 2022;13:846753.
- 418 6. Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, et al.
419 B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination
420 Among Patients Treated With Rituximab. *Arthritis & rheumatology (Hoboken, NJ)*. 2021.
- 421 7. Schrezenmeier E, Rincon-Arevalo H, Stefanski AL, Potekhin A, Straub-Hohenbleicher
422 H, Choi M, et al. B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney
423 Transplant Recipients. *J Am Soc Nephrol*. 2021;32(12):3027-33.
- 424 8. Fabris M, De Marchi G, Domenis R, Caponnetto F, Guella S, Dal Secco C, et al. High T-
425 cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
426 *Journal of autoimmunity*. 2022;129:102827.
- 427 9. Schubert M, Bertoglio F, Steinke S, Heine PA, Ynga-Durand MA, Maass H, et al.
428 Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding
429 to the RBD of SARS-CoV-2 Omicron variant. *BMC Med*. 2022;20(1):102.
- 430 10. Rose R, Neumann F, Müller S, Bäumler C, Schäfer M, Schön F, et al. Delta or Omicron
431 BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection.
432 *Allergy*. 2022.
- 433 11. Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes? *Nature Reviews*
434 *Microbiology*. 2022;20(4):187-8.
- 435 12. Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, et al.
436 Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits
437 strong immunity against SARS-CoV-2 Omicron variant. *Nature communications*.
438 2022;13(1):2670.
- 439 13. Bauer G. High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2:
440 potential relevance for protective humoral immunity. *Exploration of Immunology*.
441 2022;2(2):113-56.
- 442 14. Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for
443 protective immunity towards SARS-CoV-2. *International Journal of Infectious Diseases*.
444 2021;106:61-4.
- 445 15. Korn J, Schackermann D, Kirmann T, Bertoglio F, Steinke S, Heisig J, et al. Baculovirus-
446 free insect cell expression system for high yield antibody and antigen production. *Scientific*
447 *reports*. 2020;10(1):21393.
- 448 16. Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2
449 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors
450 binding at RBD-ACE2 interface. *Nature communications*. 2021;12(1):1577.
- 451 17. Bacher P, Heinrich F, Stervbo U, Nienen M, Vahldieck M, Iwert C, et al. Regulatory T
452 Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans. *Cell*.
453 2016;167(4):1067-78.e16.
- 454 18. Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, et al. Human
455 Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against *Candida albicans*.
456 *Cell*. 2019;176(6):1340-55.e15.
- 457 19. Bacher P, Rosati E, Esser D, Martini GR, Saggau C, Schiminsky E, et al. Low-Avidity
458 CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe
459 COVID-19. *Immunity*. 2020;53(6):1258-71.e5.

- 460 20. Bacher P, Schink C, Teutschbein J, Kniemeyer O, Assenmacher M, Brakhage AA, et al.
461 Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive
462 and memory Th cell repertoire. *Journal of immunology (Baltimore, Md : 1950)*.
463 2013;190(8):3967-76.
- 464 21. Neumann F, Rose R, Römpke J, Grobe O, Lorentz T, Fickenscher H, et al. Development
465 of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of
466 Concern or Vaccination. *Vaccines*. 2021;9(7):700.
- 467 22. Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A. Humoral
468 immune response after different SARS-CoV-2 vaccination regimens. *BMC Medicine*.
469 2022;20(1):31.
- 470 23. Strömer A, Rose R, Schäfer M, Schön F, Vollersen A, Lorentz T, et al. Performance of a
471 Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. *Microorganisms*.
472 2021;9(1):58.
- 473 24. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant
474 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med*.
475 2022;386(7):698-700.
- 476 25. Khodadadi L, Cheng Q, Radbruch A, Hiepe F. The Maintenance of Memory Plasma
477 Cells. *Frontiers in immunology*. 2019;10:721.
- 478 26. Bernardes JP, Mishra N, Tran F, Bahmer T, Best L, Blase JI, et al. Longitudinal multi-
479 omics analyses identify responses of megakaryocytes, erythroid cells and plasmablasts as
480 hallmarks of severe COVID-19 trajectories. *Immunity*.

482

483 **Figure legends**

484

485 Figure 1: **A** Patients using TNF α blockers show reduced antibody serum levels, avidity and
486 neutralisation at different timepoints. Serum IgG antibody against SARS-CoV-2 Spike 1
487 subunit at different timepoints as single values per patient. Lines indicate the median. **B** IgG
488 avidity indices of anti-S IgGs of SARS-CoV-2. **C** Neutralising antibodies against the wild-type
489 (wt) and **D** BA.2 variant of SARS-CoV-2 at 14 days and six months after the second
490 vaccination. For BA.2 and IgG avidity, a time point 7 days after the third vaccination was
491 added (n=4 per group); values are given as individual values and median. Statistical
492 differences: Kruskal-Wallis test with Dunn's post hoc test, significant differences are
493 indicated as * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$

494

495 Figure 2: Patients using TNF α blockers show higher numbers of overall plasmablasts and
496 SARS-CoV-2 specific plasmablasts 7 days after the second vaccination. **A** Flow cytometry
497 analysis of B cell subsets at different timepoints after a vaccination against SARS-CoV-2.
498 Values are shown as cells per microlitre of blood. Boxes and whiskers indicate median and
499 95%CI. **B** SARS-CoV-2 specific plasmablasts. IgA⁺ plasmablasts **C** and SARS-CoV-2 specific **D**
500 IgA⁺ positive plasmablasts. **E** and **F**: CD138⁺ unspecific and SARS-CoV-2 specific plasmablasts
501 which resemble mature plasma cells. If not indicated otherwise, cell counts per microlitre
502 blood are shown as single values with median. Statistical differences: Kruskal-Wallis test with
503 Dunn's post hoc test, significant differences are indicated as * $P < 0.05$, ** $P < 0.01$,
504 **** $P < 0.0001$

505

506 Figure 3: Antibody secreting cells (ASC) measured in 3-colour-Fluorospot 7 days after the
507 second vaccination. See figure S3 for representative image. **A** Number of total and SARS-
508 CoV-2 specific ASCs per μ L blood. **B** Spot size distribution. Single points resemble the mean






509 spot size per spot of one donor. Correlation (Pearson) of the number of SARS-Cov-2 specific
510 ASCs **C** against SARS-CoV-2 specific plasma blasts in flow cytometry and **D** against SARS-CoV-
511 2 serum IgG. Statistical differences: Kruskal-Wallis test with Dunn's post hoc test, significant
512 differences are indicated as **P<0.05*, ****P<0.001*








513



514 Figure 4: SARS-CoV-2 specific memory T cells in patients receiving TNF α blockers show a
515 delayed activation status. Antigen-reactive T cell enrichment was performed two months
516 after the second vaccination. **A** Frequencies of spike-reactive CD154+ memory cells within
517 CD4+ T cells. **B** Percentage of cytokine production within spike-reactive CD154+ memory
518 cells. **C** Percentage of PD-1 and Ki-67 positive cells within CD154+ memory cells. Each dot
519 represents one donor, lines indicate mean values. Statistical differences: Kruskal-Wallis test
520 with Dunn's post hoc test, significant differences are indicated as ***P<0.01*

521


522

A**B****C****D**









C Correlation of SARS-CoV-2 specific ASCs and serum IgG



D Correlation of SARS-CoV-2 specific ASCs and PC



A**C**

- Control
- anti-TNF α
- other DMARDs

B